BIOTECH CATALYST AI SCANNER — June WK3

This week the tape, not the calendar, sets the mood. Almost every name on the featured board walks into its catalyst beaten down — RSIs clustered in the teens to mid-40s, twenty-one-day momentum negative across nine of the top ten. Celcuity is the sharpest example: a company with pivotal data in hand and a July PDUFA, trading at an RSI of 16 after shedding nearly a third of its value in a month. When the whole list looks oversold heading into binary events, the question shifts from "is the data good" to "how much bad news is already in the price."

The regulatory cluster is the real story. Three of the top ten are filing or facing the FDA inside the next six weeks — Celcuity's gedatolisib PDUFA on July 17, Larimar's nomlabofusp rolling BLA in June, and DBV's Viaskin Peanut BLA due by June 30 — and DBV's window is sharpened by Palforzia leaving the market July 31. Against those de-risked-ish filings sits a second tier of pure binary readouts where survival and data land on the same day: Tvardi at ten months of cash, Palatin at four and a half after a 1-for-50 reverse split, Actuate running on fumes on the watchlist.

One name has been pulled from the ranking outright. RNA screened in the featured top ten off a stale catalyst feed — but the ticker now belongs to Atrium Therapeutics, a preclinical cardiology spinoff, while the del-brax FSHD program that triggered the score belongs to Novartis after its Avidity buyout. There is no live catalyst for the company actually trading under RNA, so we removed it; the featured list runs nine this week rather than pad it with a weaker name. A second correction stays on the watchlist for transparency: uniQure (QURE) appears on an AMT-162 ALS catalyst that no longer exists — the program was discontinued in 2025 — and is written straight below as a do-not-trade. The screen is a starting point, not gospel; this is the part where a human reads the filings.

What We're Tracking:

Trading Below Cash: KTTA, ACET
Cash Pressure: PTN, TVRD, DBVT, ACTU, BHVN, VSTM, AIM
Initial / First-in-Human Data: IRD, ALLO, TVRD, ACTU, CGON
Multi-Catalyst: None flagged this week

#1. IRD — Opus Genetics Inc.

THE CATALYST
Event: Phentolamine Ophthalmic Solution 0.75% (LYNX-3) — Phase 3 Topline Data in post-surgical dim-light vision loss
Date: Q2 2026 (Est.)
FDA Status: FTD
BSI: 8.3/10

The market values Opus as a gene-therapy story and treats this small-molecule eye drop as a sideshow — which is exactly why the readout is interesting. Opus was formed by the October 2024 all-stock merger of Ocuphire Pharma into Opus Genetics, pairing AAV-based gene therapies for inherited retinal disease with a clinical-stage ophthalmic drug franchise. It filed a supplemental NDA for the same drug in presbyopia in December 2025 and closed a $25M private placement led by Adage Capital in February 2026, extending its runway well past this catalyst.

📈 The Setup: People who've had LASIK or PRK can be left with poor night vision — glare and halos in dim, low-contrast conditions — and there is no approved drug for it. Phentolamine Ophthalmic Solution 0.75% is a non-selective alpha-adrenergic antagonist (it shrinks the pupil without engaging the focusing muscle, unlike presbyopia miotics such as Vuity). The companion LYNX-2 trial already hit its mark: 17.3% of treated patients gained at least 15 letters of dim-light, low-contrast acuity at Day 15 versus 9.2% on placebo (p<0.05). LYNX-3 copies that design — randomized, double-masked, roughly 200 post-refractive patients, run under an FDA Special Protocol Assessment (a binding agreement on trial design). A clean replication completes the two-trial package for filing. This is initial data on a second pivotal, not a make-or-break event — the franchise already has a presbyopia filing in motion.

✅ The Edge: LYNX-2 already cleared the identical endpoint in the identical population under an SPA and Fast Track. A second trial replicating a pre-agreed design is a far lower bar than a typical Phase 3 — and there's no approved competitor in this specific post-surgical indication to benchmark against.
⚠️ The Risk: The win in LYNX-2 was modest in absolute terms — an 8-point responder gap. If placebo response drifts up under the LYNX-3 protocol, that margin is thin enough to vanish, and FDA could still press for a functional night-driving endpoint the primary analysis doesn't capture.

#2. CELC — Celcuity Inc.

THE CATALYST
Event: Gedatolisib + Fulvestrant (VIKTORIA-1) — PDUFA Regulatory Decision in HR+/HER2- Advanced Breast Cancer
Date: Jul 17, 2026
FDA Status: BTD, FTD
BSI: 8.0/10

Celcuity heads into a July decision holding what single-asset oncology companies rarely have: pivotal data that works in both halves of its target population. The NDA under review covers the PIK3CA wild-type group, and the separately reported mutant-cohort win opens a second filing on top of it. The company licenses gedatolisib from Pfizer, carries an unusually deep cash position for its stage, and is already building a commercial organization while pushing into first-line treatment via the VIKTORIA-2 trial.

📈 The Setup: HR+/HER2- breast cancer that progresses after CDK4/6 inhibitors splits into PIK3CA-mutant and wild-type camps, and most targeted drugs serve only the mutant side — the wild-type majority has no targeted option. Gedatolisib is an intravenous pan-PI3K/mTOR inhibitor (it blocks every class-I PI3K isoform plus both mTOR complexes, rather than one mutation), designed to shut down the whole growth pathway and limit the escape routes single-target drugs leave open. In VIKTORIA-1's mutant cohort, the gedatolisib triplet and doublet reached 11.1 and 11.3 months median progression-free survival versus 5.6 for alpelisib (Piqray) plus fulvestrant, with response rates running far higher. The wild-type cohort — the basis for the July 17 decision under Real-Time Oncology Review — cleared its bar separately. With the stock at an RSI of 16 and down nearly a third into the date, the market is pricing approval risk the published data don't obviously support.

✅ The Edge: Gedatolisib is the only pan-PI3K/mTOR agent with positive pivotal data in both wild-type and mutant disease — a dual-label opportunity from one trial that isoform-selective alpelisib and the AKT inhibitor capivasertib can't match. Breakthrough and Fast Track designations plus an RTOR review underline FDA engagement.
⚠️ The Risk: Class tolerability is the soft spot. Stomatitis and related PI3K/mTOR toxicities could throttle real-world uptake against entrenched alpelisib in mutant patients, and any safety imbalance could push FDA to a narrower wild-type-only label than the data breadth suggests.

#3. PTN — Palatin Technologies Inc.

THE CATALYST
Event: Bremelanotide + PDE5i — Topline Data in PDE5i-resistant erectile dysfunction
Date: Q2 2026 (Est.)
BSI: 7.9/10

This is a survival story wearing a science story's clothes. Palatin executed a 1-for-50 reverse split in August 2025 to defend its listing, which is why the float reads at well under two million shares and the per-share price looks healthy against a $24M market cap. The company pivoted its strategic focus to obesity — melanocortin-4 agonists and a Boehringer Ingelheim collaboration — after selling Vyleesi (bremelanotide) rights to Cosette in 2024 and sublicensing its dry-eye asset in January 2026. The ED combo is the nearest-term shot on goal, and with roughly four and a half months of cash, time is the binding constraint.

📈 The Setup: Standard oral ED pills — Viagra, Cialis — do nothing for the 30-40% of patients who don't respond to them, and nothing approved targets that gap. Palatin's answer combines bremelanotide, a melanocortin-4 receptor agonist (it drives erection through a central nervous-system pathway, not the blood-vessel relaxation that PDE5 inhibitors rely on), with a PDE5 inhibitor in a single injection, betting the two mechanisms stack in non-responders. Earlier crossover work suggested that synergy. One caution worth stating plainly: the study Palatin actually disclosed initiating was Phase 2, even as the company has guided to "Phase 3 topline" in the first half of 2026 — so treat the staging label with care. Either way, this is a binary readout for a company with months, not years, of runway, and essentially no other near-term catalyst after the obesity pivot.

✅ The Edge: No other late-stage program targets PDE5i non-responders with a melanocortin combination — the competitive field is generic oral pills and an unrelated novel PDE5i (TPN171H) that isn't aimed at this population. The single-injection co-formulation is the differentiator.
⚠️ The Risk: With about $6.6M in the bank, a delayed or ambiguous readout forces financing from a sub-$25M-cap shell — brutal terms against a 1.78M-share float. And the program's disclosed stage doesn't clearly match the "Phase 3 topline" framing, which raises the odds FDA later asks for a larger combination safety database.

#4. LRMR — Larimar Therapeutics Inc.

THE CATALYST
Event: Nomlabofusp (CTI-1601) — BLA Submission (accelerated approval) in Friedreich's Ataxia
Date: Q2 2026 (Est.)
FDA Status: BTD, ODD
BSI: 7.8/10

Larimar carries the kind of regulatory tailwind the market hasn't fully priced. The lead program is a frataxin replacement for Friedreich's ataxia, a rare inherited disease that progressively robs patients of coordination, and a February 2026 upsized offering brought in new healthcare investors alongside a fresh Breakthrough Therapy Designation. The company also runs an intracellular protein-delivery platform aimed at additional rare diseases, but the FA filing is the whole story near-term.

📈 The Setup: The only approved FA therapy, omaveloxolone (Skyclarys, Biogen), modulates oxidative stress symptomatically — it doesn't touch the underlying problem, which is too little frataxin, a protein that mitochondria need to function. Nomlabofusp is a recombinant fusion protein engineered with a cell-penetrating peptide and a mitochondrial-targeting tag to deliver mature frataxin directly inside cells. In the open-label extension (n=39), daily subcutaneous dosing raised skin frataxin from a median 16.5% to 82.2% of healthy-control levels — into the range seen in symptom-free genetic carriers — over six months, while four clinical measures all drifted in the right direction. FDA has aligned with Larimar on using skin frataxin as a surrogate endpoint "reasonably likely" to predict benefit, which is what makes a June rolling BLA for accelerated approval realistic rather than aspirational.

✅ The Edge: This is the only FA program with Breakthrough designation, confirmed FDA alignment on a novel surrogate endpoint, and a rolling BLA in flight — most rivals sit in earlier-stage trials without comparable regulatory clarity. Raising frataxin into carrier range is something no prior FA drug has demonstrated.
⚠️ The Risk: The safety database includes seven anaphylaxis cases, all early in dosing, and FDA could judge it too thin at review or demand confirmatory clinical data the directional trends don't yet guarantee. Manufacturing scale-up for the CMC module — due in the second half — is the other gating item.

#5. LYEL — Lyell Immunopharma Inc.

THE CATALYST
Event: LYL273 (GCC19CART) — Phase 1 Data Update in Metastatic Colorectal Cancer
Date: Q2 2026 (Est.)
BSI: 7.3/10

Lyell bought its way into an overlooked data set. In November 2025 it acquired global rights (ex-Greater China) to LYL273 from Innovative Cellular Therapeutics in a deal worth roughly $185M including milestones — a U.S. Phase 1 program that had generated striking early numbers with little investor attention. The company also runs ronde-cel (LYL314) in a pivotal head-to-head trial for relapsed/refractory large B-cell lymphoma, giving it a second, later-stage shot on goal.

📈 The Setup: No CAR-T therapy is approved for solid tumors, and refractory colorectal cancer is among the hardest cases — standard options like regorafenib and trifluridine/tipiracil deliver single-digit response rates. LYL273 is an autologous CAR-T (a patient's own T-cells re-engineered to attack a target) aimed at guanylyl cyclase-C, a receptor expressed on more than 95% of colorectal tumors, with added engineering to help the cells survive the hostile tumor environment. In the early U.S. Phase 1 (N=12 as of the October 2025 cutoff), the second dose level produced a 67% response rate and 83% disease-control rate with 7.8-month median progression-free survival — figures that tower over the standard-of-care bar. The next data update, due in the first half of 2026, has to show those responses hold up as more patients and higher doses come in.

✅ The Edge: A 67% response rate in refractory colorectal cancer is unheard-of for this setting, and GCC's near-universal expression in the tumor type gives the target unusual reach. Fast Track is in hand, and Lyell acquired the asset cheaply relative to the signal.
⚠️ The Risk: The dose that produced 67% also carried a dose-limiting toxicity that included a death from fungal sepsis, with cytokine release in 83% of patients — so the efficacy and safety story are entangled at the same dose. With only twelve patients and no durability beyond 7.8 months, the responses could prove transient or the therapeutic window too narrow as escalation continues.

#6. KTTA — Pasithea Therapeutics Corp.

THE CATALYST
Event: PAS-004 — Phase 1 Interim Data (Cohorts 4-8) in MAPK-driven cancers
Date: Q2 2026 (Est.)
BSI: 7.3/10

The unusual fact here is the balance sheet: Pasithea holds more cash ($46.57M) than its entire market value ($19.39M), so the market is assigning negative value to the pipeline. The company's lead is a next-generation oral MEK inhibitor, with lead indication in neurofibromatosis type 1 plexiform neurofibromas (NF1-PN, benign but disfiguring nerve-sheath tumors) plus expansion into MAPK-driven cancers and ALS. A $60M raise closed in December 2025, and the drug holds Fast Track and Rare Pediatric Disease designations in NF1-PN and Orphan Drug status in ALS. No partnerships are disclosed.

📈 The Setup: Two MEK inhibitors already define the NF1-PN market — selumetinib (Koselugo, AstraZeneca) and mirdametinib (Gomekli, SpringWorks) — and the class is notorious for rash and eye toxicities that limit dosing. PAS-004 is a macrocyclic oral MEK1/2 inhibitor (it blocks a node in the MAPK growth-signaling cascade) whose pitch is a long ~70-hour half-life that gives flat, steady drug exposure and, in theory, a gentler tolerability profile. Interim Phase 1 data in heavily pretreated solid-tumor patients showed mostly stable disease — 10 of 16 evaluable — with modest tumor shrinkage in a KRAS-mutant pancreatic case and a BRAF-mutant melanoma case after prior MEK/BRAF therapy. The Q2 follow-up from the higher-dose cohorts (15-45 mg) is what matters: it needs to convert "stable disease" into actual responses to justify the differentiation claim. This is early, exploratory data — treat it accordingly.

✅ The Edge: The cash-above-market-cap setup means downside is partly cushioned by the balance sheet while the pharmacokinetic profile — once-daily, flat exposure — is a genuine point of separation from approved MEK drugs with narrower windows.
⚠️ The Risk: Stable disease in 21 patients is not yet evidence of differentiation, and the prior data showed no confirmed objective responses. If the higher doses bring the class-typical rash and ocular toxicity without responses, PAS-004 looks like a me-too behind two entrenched, already-approved competitors.

#7. TVRD — Tvardi Therapeutics Inc.

THE CATALYST
Event: TTI-109 — Phase 1 First-in-Human Topline Data (healthy volunteers)
Date: Q2 2026 (Est.)
BSI: 7.2/10

Tvardi develops oral STAT3 inhibitors for fibrosis and inflammation, and it reached the public market by an unusual route: a 2025 reverse merger with the former Cara Therapeutics. The stock sits near its post-merger lows, with ten months of cash, no disclosed partnerships, and a pipeline organized around lead asset TTI-101 (in Phase 2 for liver cancer and idiopathic pulmonary fibrosis) plus the next-generation TTI-109. The June readout is a de-risking checkpoint for the whole platform, not a pivotal outcome.

📈 The Setup: STAT3 is a transcription factor that sits at the crossroads of fibrosis, inflammation and tumor survival, and drugging it orally has historically been hard — direct inhibitors are scarce, which is part of Tvardi's pitch. TTI-109 is an oral STAT3 inhibitor designed as a prodrug of TTI-101 — same active molecule, reformulated for better tolerability and broader dosing. The June healthy-volunteer topline is a safety, pharmacokinetics and bioequivalence test: does the next-gen version deliver the same drug exposure with a cleaner profile, clearing the way for Phase 2? The benchmark to beat sits in idiopathic pulmonary fibrosis, where Ofev (nintedanib) and Esbriet (pirfenidone) set a high tolerability and efficacy bar that any new fibrosis drug must eventually clear. The prior TTI-101 Phase 1 in solid tumors (n=64) was well tolerated with linear pharmacokinetics and a 12% confirmed response rate.

✅ The Edge: Oral STAT3 inhibitors are rare, and TTI-101/109 are among the most advanced. A clean bioequivalence-and-tolerability package would hand Tvardi a better-dosed backbone to take into fibrosis or oncology Phase 2 without re-running the mechanism risk.
⚠️ The Risk: This is a small, short healthy-volunteer study — any unexpected adverse-event signal or PK variability stalls the development plan for a company with ten months of cash. And even a clean readout only buys a Phase 2 entry into IPF, where it would have to prove superiority over two entrenched standards.

#8. ALLO — Allogene Therapeutics Inc.

THE CATALYST
Event: ALLO-329 (RESOLUTION) — Phase 1 First-in-Human Data in Autoimmune Disease
Date: Q2 2026 (Est.)
FDA Status: FTD
BSI: 7.1/10

Allogene can afford to be patient in a way most of this board can't — nearly nine years of runway on the screen's math, the product of a large cash position and a low burn relative to its size. The company builds off-the-shelf, donor-derived CAR-T therapies (engineered immune cells made from healthy donors rather than the patient) and holds U.S. and EU rights to certain Cellectis gene-editing technology. An April 2026 raise topped up resources ahead of this readout, and ALLO-329 already carries three Fast Track designations across lupus, myositis and scleroderma.

📈 The Setup: Autologous CAR-T has shown dramatic results in autoimmune disease, but it's bespoke, slow and requires heavy chemotherapy conditioning. Allogene's bet is to make it off-the-shelf. ALLO-329 is a CRISPR-edited dual CAR-T expressing both anti-CD19 and anti-CD70, where the anti-CD70 arm — its "Dagger" technology — is designed to fend off the patient's immune rejection of the donor cells. An April 2026 Nature Communications paper showed that in animal models the cells expanded and persisted, wiped out B-cells and activated T-cells, and halted autoantibody production. The RESOLUTION basket trial runs two cohorts — reduced lymphodepletion and, notably, none at all. If the no-conditioning arm shows real immune cell depletion in patients, that would be a first for allogeneic CAR-T in autoimmune disease and the cleanest point of separation from autologous rivals like Kyverna. This is first-in-human data, so read it as proof-of-concept, not efficacy.

✅ The Edge: The cash position lets Allogene run multiple readouts without forced financing, and the no-lymphodepletion design is genuinely differentiated — every approved and most investigational CAR-T regimens require conditioning chemotherapy. Eliminating it would change the convenience math against biologics like belimumab.
⚠️ The Risk: Allogeneic persistence is the unproven part — if the Dagger edit doesn't hold off rejection and the cells fail to expand or deplete B-cells at the first dose, the off-the-shelf thesis loses its main advantage versus autologous programs already showing autoimmune responses.

#9. DBVT — DBV Technologies S.A.

THE CATALYST
Event: Viaskin Peanut (VITESSE) — BLA Submission in pediatric peanut allergy (ages 4-7)
Date: Q2 2026 (Est.)
BSI: 7.0/10

This is a comeback bid with a history the market hasn't forgotten. DBV is a France-domiciled company (its shares trade on Nasdaq as ADSs) focused on epicutaneous immunotherapy — treating allergy through a skin patch. It received a Complete Response Letter on this same Viaskin Peanut patch in 2020 over manufacturing and patch-adhesion questions, and the stock still carries that scar tissue. A March 2025 PIPE financing plus warrant exercises tied to the trial's success extended cash visibility into 2027, setting up a second run at the FDA.

📈 The Setup: The peanut-allergy treatment landscape is about to thin out: Palforzia, the only approved oral immunotherapy, is being pulled from the market on July 31, 2026 by Stallergenes Greer. That hands DBV a near-empty lane just as it files. Viaskin Peanut delivers peanut protein through a skin patch to gradually desensitize children — its differentiation from oral immunotherapy is avoiding daily ingestion and the systemic reactions that come with it. In the Phase 3 VITESSE trial (n≈654, ages 4-7), 46.6% of treated children met the desensitization threshold versus 14.8% on placebo at month 12, and 83% increased the amount of peanut they could tolerate versus roughly 48% on placebo. Critically, FDA agreed in March 2025 that VITESSE's safety exposure alone supports the BLA, removing a previously required supplemental study — a direct answer to the issues behind the 2020 CRL. The filing is due by June 30.

✅ The Edge: Viaskin is the only epicutaneous candidate in late-stage filing for the 4-7 group, and Palforzia's July exit clears the closest competitor from the field. FDA's concession on the safety package directly addresses the 2020 rejection's core objection.
⚠️ The Risk: The 2020 CRL was about manufacturing consistency and patch adhesion — exactly the questions that could resurface during BLA review, since real-world adhesion across different skin types and caregivers is harder to control than trial conditions. And Palforzia's own weak commercial uptake is a warning that approval and adoption are different things.

WATCHLIST

#10. ACTU — Actuate Therapeutics Inc. [Oncology]

Price: $1.95 | Cap: $46.66M | Cash: $4.12M | RSI: 26.3 | Momentum: -32.5%
Elraglusib + FOLFIRINOX + losartan — Phase 2 data in metastatic pancreatic cancer (Q2 2026 Est.)
BSI: 7.0/10

The Intel: Note the screened catalyst is a secondary read: Actuate's headline elraglusib Phase 2 — paired with gemcitabine/nab-paclitaxel — already reported positive in January 2026 (a 38% reduction in risk of death versus chemo alone, published in Nature Medicine), so the company's main de-risking event is behind it. Elraglusib is a GSK-3β inhibitor (it blocks a kinase that helps tumors survive chemotherapy); this Q2 catalyst is a separate combination layering it onto FOLFIRINOX with losartan to soften the dense stroma walling off pancreatic tumors. With about $4M in cash, the financing overhang outweighs an incremental combination readout — the durable survival signal that matters most has already printed elsewhere.

#11. BHVN — Biohaven Ltd. [Neurology]

Price: $11.07 | Cap: $1.67B | Cash: $227.88M | RSI: 63.4 | Momentum: +20.3%
BHV-7000 — Phase 2/3 data in focal epilepsy (Q2 2026 Est.)
BSI: 7.0/10

The Intel: One of the few names on the board with positive momentum (RSI 63, up 20% in a month). BHV-7000 activates Kv7 potassium channels — proteins that calm overexcitable nerve firing — with selective Kv7.2/7.3 targeting meant to avoid the sedation and mood effects that sink many anti-seizure drugs, and the skin-pigmentation problems that derailed the earlier Kv7 agonist ezogabine. Early Phase 1 showed clean CNS tolerability. The competitive field in epilepsy is crowded with generics, so differentiation rests entirely on that side-effect profile holding up at efficacious doses.

#12. FATE — Fate Therapeutics Inc. [Autoimmune / Cell Therapy]

Price: $1.87 | Cap: $217.97M | Cash: $150.16M | RSI: 50.7 | Momentum: -16.9%
FT819 — Phase 1 conference update in systemic lupus erythematosus (Jun 30, 2026)
BSI: 6.8/10

The Intel: FT819 is an off-the-shelf, iPSC-derived CD19 CAR-T (immune cells grown from a renewable master cell line rather than each patient's own) aimed at resetting immunity in lupus. The early read is encouraging: in a newly presented cohort, all three treated patients hit an SRI-4 response and two reached low disease activity — without conditioning chemotherapy, the same convenience angle Allogene is chasing. FDA selected FT819 for a CMC manufacturing pilot in May. Against autologous lupus CAR-T programs showing deeper datasets, Fate's edge is scalable manufacturing — but the patient numbers here are still tiny.

#13. VSTM — Verastem Inc. [Oncology]

Price: $3.76 | Cap: $330.40M | Cash: $139.99M | RSI: 39.9 | Momentum: -18.8%
VS-7375 (GFH375) — Phase 1/2 interim data in KRAS G12D solid tumors (Q2 2026 Est.)
BSI: 6.8/10

The Intel: VS-7375 is an oral KRAS G12D inhibitor — targeting a mutation that drives pancreatic, colorectal and lung cancers and that, unlike the G12C variant, still has no approved drug. Earlier reads pointed to a 68.8% response rate in NSCLC at the recommended dose, though those came from the partner's China data and need replication in the broader population. Verastem is racing a field that includes Revolution Medicines' pan-RAS program, the deeper-pocketed competitor that's the real long-term threat. Cash pressure and negative momentum temper the setup despite the eye-catching early numbers.

#14. AIM — AIM ImmunoTech Inc. [Oncology]

Price: $0.44 | Cap: $10.65M | Cash: $6.10M | RSI: 57.2 | Momentum: +50.9%
Ampligen (rintatolimod) + Imfinzi (durvalumab) (DURIPANC) — Phase 2 data in metastatic pancreatic cancer (Mid-2026 Est.)
BSI: 6.8/10

The Intel: A sub-$11M micro-cap that's run 51% in a month on a June update. The DURIPANC trial pairs Ampligen, a TLR3 agonist meant to switch on innate antiviral-style immunity, with AstraZeneca's checkpoint inhibitor Imfinzi to try to make "cold" pancreatic tumors visible to the immune system. The combination is genuinely novel, but the data are early-stage in a tiny number of post-FOLFIRINOX stable-disease patients, and pancreatic immunotherapy is a graveyard of promising combinations. At $6M cash, the momentum is sentiment, not validation — size accordingly.

#15. ACET — Adicet Bio Inc. [Autoimmune / Cell Therapy]

Price: $7.31 | Cap: $68.34M | Cash: $120.40M | RSI: 44.9 | Momentum: -8.1%
Prula-cel (ADI-001) — Phase 1 interim data in systemic sclerosis (Q2 2026 Est.)
FDA Status: FTD
BSI: 6.7/10

The Intel: Another cash-above-market-cap name — $120M in the bank against a $68M cap, so the pipeline is valued below zero. Prula-cel is an off-the-shelf gamma-delta CAR-T (a less common immune-cell type that naturally homes to tissue) targeting CD20+ B-cells to halt the fibrosis and autoimmunity of systemic sclerosis. The tissue-homing biology is the differentiation pitch versus conventional alpha-beta CAR-T. Fast Track is in hand. With autoimmune CAR-T crowded by CD19 approaches, the gamma-delta, CD20 angle is the bet — interim Phase 1 needs to show it translates.

#16. CGON — CG Oncology, Inc. [Oncology]

Price: $54.92 | Cap: $4.84B | Cash: $1.03B | RSI: 27.8 | Momentum: -23.8%
Cretostimogene (PIVOT-006) — Phase 3 topline in non-muscle-invasive bladder cancer (Q2 2026 Est.)
BSI: 6.7/10

The Intel: The largest name on the watchlist by far — a near-$5B cap with $1B in cash, oversold at RSI 28. Cretostimogene is an oncolytic adenovirus (an engineered virus that replicates inside and ruptures tumor cells with a defective Rb pathway) delivered straight into the bladder. PIVOT-006 tests it after surgery in intermediate-risk disease, while an expanded-access program covers BCG-unresponsive patients. The bladder-cancer field is heating up with several intravesical and systemic entrants, but CG's balance sheet and lead position make this the watchlist's most de-risked setup despite the negative tape.

#17. CGTX — Cognition Therapeutics Inc. [Neurology]

Price: $1.14 | Cap: $102.03M | Cash: $26.70M | RSI: 38.5 | Momentum: -3.4%
Zervimesine (CT1812) — End-of-Phase-2 meeting in dementia with Lewy bodies (Q2 2026 Est.)
BSI: 6.6/10

The Intel: Zervimesine is a sigma-2 receptor modulator designed to pry toxic amyloid-beta clumps off neuronal synapses, aiming to protect cognition rather than just ease symptoms. The headline draw is the Phase 2 SHIMMER result — an 86% slowing of decline on a behavioral scale versus placebo — though that came from a small study and the effect size invites caution. The catalyst here is a regulatory milestone (an FDA end-of-Phase-2 meeting), not new data, so it's about path-forward clarity in a notoriously failure-prone neurodegeneration space rather than a fresh readout.

#18. QURE — uniQure N.V. [Neurology / Gene Therapy]

Price: $26.82 | Cap: $1.69B | Cash: $109.40M | RSI: 57.2 | Momentum: -7.8%
AMT-162 — Phase 1 data in SOD1-ALS (Q2 2026 Est.)
BSI: 6.6/10

The Intel — correction. The scanner lists QURE on an AMT-162 SOD1-ALS readout, but that program was discontinued in 2025: uniQure paused enrollment in the EPISOD1 trial after an independent committee flagged a dose-limiting toxicity in a higher-dose patient, and after reviewing the data the company ended development with only five patients dosed. There is no live catalyst here. The company's actual value sits with AMT-130, its gene therapy for Huntington's disease, where it is working through an FDA path. Don't trade the AMT-162 headline — it points to a dead asset.

#19. LIXT — Lixte Biotechnology Holdings Inc. [Oncology]

Price: $6.89 | Cap: $103.49M | Cash: $18.35M | RSI: 64.8 | Momentum: +35.9%
LB-100 + doxorubicin — Phase 1b/2 initial data in ovarian clear cell carcinoma (Q2 2026 Est.)
BSI: 6.6/10

The Intel: The other momentum name (up 36%, RSI 65). LB-100 inhibits PP2A — a phosphatase that helps cells repair DNA damage — to make ovarian clear cell carcinoma more vulnerable to doxorubicin chemotherapy. The trial focuses on ARID1A-mutated tumors, a genetically defined subset where the synthetic-lethality rationale is strongest. It's a first-in-class mechanism with a clear biological hypothesis, but clear cell ovarian cancer is a small, chemo-resistant niche, and the early-stage data will need to show the sensitization actually translates into responses, not just a tidy mechanism.

The Strategist's Take

If you're hunting quality over lottery tickets, the regulatory tier earns the attention this week. Celcuity (BSI 8.0) is the cleanest setup on the board — pivotal data that works in both PIK3CA-mutant and wild-type breast cancer, a July 17 PDUFA, and a stock so oversold (RSI 16, down a third in a month) that the market is pricing approval risk the published data don't obviously justify. Larimar (7.8) and DBV (7.0) round out the filing names: a frataxin-replacement BLA with FDA buy-in on a novel surrogate, and a peanut patch refiling into a lane Palforzia vacates on July 31. None of these are make-or-break binaries — they're companies presenting from positions of relative strength.

A word on calibration. These BSI scores carry a +1.00 manual adjustment this week, which flatters the bottom of the board more than the fundamentals warrant — read the raw screen as running roughly a point lower. The adjustment is most generous to the watchlist names sitting at a calibrated 6.6-7.0: Actuate, QURE and Lixt look stronger on the number than their setups support. Weigh the writeup, not the digit.

Below that, the board splits between intriguing science and real fragility. Opus (8.3) tops the ranking on the strength of an already-replicated endpoint, and Lyell (7.3) carries the most arresting number on the page — a 67% response rate in refractory colorectal cancer — but read that one with the dose-limiting toxicity and the treatment-related death sitting at the very same dose. Pasithea (7.3) and Adicet (6.7) are the cash-above-market-cap names where the balance sheet, not the data, is the floor. And the pressure-cooker tier is exactly that: Tvardi at ten months of cash, Palatin at four and a half after a 1-for-50 reverse split and with a program whose disclosed stage (Phase 2) doesn't match its "Phase 3 topline" guidance, Actuate at four million dollars. For these, the runway underneath the readout matters more than the readout.

Two corrections the ranking forced, and they're the most important thing in this issue. RNA was pulled from the featured list entirely — it is not a del-brax FSHD play; the ticker now belongs to Atrium Therapeutics, a preclinical cardiology spinoff with no human data until 2027, while del-brax went to Novartis in the Avidity acquisition. We'd rather run nine clean names than rank a phantom one. uniQure (#18) stays on the watchlist as a flagged do-not-trade: its AMT-162 ALS catalyst no longer exists — the program was discontinued in 2025 after a dose-limiting toxicity — and the company's value lives with AMT-130 in Huntington's. Both are artifacts of a catalyst feed that attached events to tickers whose underlying assets have changed hands or been killed. A third, milder version sits at watchlist #10: Actuate's headline elraglusib survival data already printed in January, so its "Q2 initial data" line points to a secondary trial, not the event that matters. The lesson repeats every few weeks: the BSI score is a screen, not a recommendation, and the filings are where the truth is. This week the calendar points at Q2 readouts, but the cap table and the corporate history tell you which catalysts are even real.

About This Scanner

This weekly report identifies biotech catalyst opportunities using quantitative screening combined with fundamental analysis.

What the Score Means: The BSI Score (0-10) reflects overall opportunity quality based on technical setup and fundamental characteristics. Higher scores indicate more favorable setups; lower scores indicate elevated uncertainty. This is NOT a prediction of catalyst outcomes or stock direction.

Data Sources: Financial data from market feeds and regulatory filings. Catalyst dates are estimates based on company guidance and subject to change. Note: this week's run surfaced two stale or misattributed catalysts (RNA, QURE), corrected manually above against current filings — a reminder that screen output requires fundamental verification before acting.

Important: This report is for informational and educational purposes only. It does not constitute investment, financial, or medical advice. Conduct your own due diligence before making investment decisions.

Disclaimer

The information provided is for informational purposes only and should not be construed as financial, investment, legal, or professional advice.

Key Risks:

Clinical trials: Most drug candidates fail in development
Regulatory: FDA decisions remain unpredictable
Financing: Companies may dilute at any time
Volatility: Small-cap biotech stocks experience extreme price swings

Past performance does not guarantee future results.

Scanner Version: 3.2 | Generated: 2026-06-11T10:30:00